F. Suzuki

发表

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Gastroenterology.

Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Advances in Therapy.

Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prolonged hepatitis after acute infection with genotype H hepatitis B virus.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes.

K. Tadokoro, Toshikazu Yamaguchi, Toru Egashira, 2006, Journal of virological methods.

Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of gastroenterology and hepatology.

Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus

K. Chayama, Yoshiyuki Suzuki, M. Kobayashi, 2012, Journal of Gastroenterology.

Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Digestive Diseases and Sciences.

Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase

Pei-Jer Chen, T. Tseng, J. Kao, 2022, The American journal of gastroenterology.

Correlation between hepatitis B virus surface antigen level and alpha‐fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, H. Kumada, 2013, Journal of medical virology.

Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with Hepatitis C Virus Genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Infection Treatment of Hepatitis C Virus Genotype 1 Variants for Prediction of Efficacy of Utility of Detection of Telaprevir-Resistant

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013 .

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon‐alpha‐2b and ribavirin in hepatitis C patients

Yoshiyuki Suzuki, H. Tsuda, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Emergence of telaprevir‐resistant variants detected by ultra‐deep sequencing after triple therapy in patients infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of medical virology.

Long‐term interferon monotherapy reduces the risk of HCV‐associated hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non‐responders infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Intervirology.

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.

Yusuke Nakamura, K. Chayama, Y. Karino, 2011, The Journal of infectious diseases.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2010, Hepatology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino Acid Substitutions in HCV Core Region as Predictor of Mortality after First Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

The Efficacy of 24-Week Interferon Monotherapy for Type C Liver Cirrhosis in Japanese Patients with Genotype 1b and Low Virus Load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare‐up

N. Hiraga, Yoshiyuki Suzuki, M. Kobayashi, 2005, Journal of medical virology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study

Yusuke Nakamura, T. Tsunoda, M. Kubo, 2013, PloS one.

Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of Gastroenterology.

Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Digestive Diseases and Sciences.

Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN

K. Chayama, Y. Karino, J. Toyota, 2012 .

Origin of neovascular structure in an early stage of hepatocellular carcinoma: Study of alpha‐smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of gastroenterology and hepatology.

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Gut and liver.

Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Hepatology International.

Correlation of Histopathological Features andGenetic Variations with Prognosis of JapanesePatients with Nonalcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, The American journal of medicine.

Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver

Yoshiyuki Suzuki, K. Kinowaki, T. Fujii, 2019, Internal medicine.

Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report

Yoshiyuki Suzuki, Y. Torisu, M. Kobayashi, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Scandinavian journal of gastroenterology.

Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of gastroenterology and hepatology.

New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2022, Oncology.

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, World journal of gastroenterology.

Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, I. Yasuda, 2021, Internal medicine.

Virological and Biochemical Relapse after Discontinuation of Lamivudine Monotherapy for Chronic Hepatitis B in Japan: Comparison with Breakthrough Hepatitis during Long-Term Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Histological Improvements after a Three-Year Lamivudine Therapy in Patients with Chronic Hepatitis B in Whom YMDD Mutants Did Not or Did Develop

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2008, Journal of Gastroenterology.

Efficacy and safety of entecavir in lamivudine‐refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients

M. Sata, F. Imazeki, M. Omata, 2008, Journal of Gastroenterology and Hepatology.

Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Pathogenic Significance and Organic Virus Levels in Patients Infected with TT Virus

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Intervirology.

Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection

A. Tsubota, Y. Suzuki, M. Kobayashi, 2004, Journal of viral hepatitis.

HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Clinical Microbiology.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all‐oral direct‐acting antiviral regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Oncology.

Efficacy and safety of telaprevir with pegylated interferon α‐2a and ribavirin in Japanese patients

H. Kumada, F. Suzuki, N. Kamiya, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

N. Hayashi, M. Kurosaki, N. Hiramatsu, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

K. Chayama, Y. Karino, M. Patwardhan, 2015, Hepatology.

Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of Clinical Microbiology.

Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of Gastroenterology.

Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies

Kazuhiko Yamamoto, M. Mizokami, A. Ido, 2016, Journal of Gastroenterology.

Telaprevir is Effective Given Every 12 H at 750 Mg with Pegylated Interferon-α2B and Ribavirin to Japanese Patients with HCV-1B Il28B Rs8099917 Tt

K. Chayama, Y. Karino, J. Toyota, 2014, Antiviral therapy.

Efficacy of telaprevir‐based therapy for difficult‐to‐treat patients with genotype 2 chronic hepatitis C in Japan

K. Chayama, T. Okanoue, J. Toyota, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, The American journal of medicine.

Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: Long‐term follow up of a pilot study

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of gastroenterology and hepatology.

Prolonged‐efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

The useful predictors of zinc deficiency for the management of chronic liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Journal of Gastroenterology.

No‐touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Magnetic resonance laparoscopy: A new non‐invasive technique for the assessment of chronic viral liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, BMC Gastroenterology.

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis

K. Chayama, M. Kurosaki, N. Hiramatsu, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Scandinavian journal of gastroenterology.

Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Oncology.

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology communications.

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, BMC Gastroenterology.

Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C.

K. Chayama, A. Tsubota, Y. Suzuki, 2001, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of a no‐touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, BMC Gastroenterology.

Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology communications.

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology communications.

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, BMC Gastroenterology.

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2019, Internal medicine.

Impact of sodium-glucose co-transporter 2 inhibitor for non-alcoholic fatty liver disease complicated by diabetes mellitus -Prospective study based on the serial liver biopsy-

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

Therapeutic effects of short‐ and intermediate‐term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Serum levels of γ-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

Rifaximin‐altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials

H. Yoshiji, T. Kawaguchi, K. Okita, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety of telaprevir with natural human interferon‐β and ribavirin in Japanese chronic hepatitis C patients with depression

K. Chayama, M. Nakamuta, H. Kumada, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Evolution of simeprevir‐resistant variants in virological non‐responders infected with HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of medical virology.

Effectiveness and safety of reduced‐dose telaprevir‐based triple therapy in chronic hepatitis C patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Evolution of simeprevir‐resistant variants over time by ultra‐deep sequencing in HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology.

Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle

K. Ikeda, M. Kobayashi, H. Kumada, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

S. Ozawa, Y. Ohno, H. Kumada, 2012, Drug metabolism and pharmacokinetics.

Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non‐B, non‐C liver cirrhosis: a cohort study

Yoshiyuki Suzuki, Y. Suzuki, K. Ikeda, 2009, Journal of viral hepatitis.

Influence of Hepatitis C Virus Subtype on Hepatocellular Carcinogenesis: A Multivariate Analysis of a Retrospective Cohort of 593 Patients with Cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of medical virology.

Successful treatment of an entecavir‐resistant hepatitis B virus variant

M. Imamura, N. Hiraga, K. Chayama, 2007, Journal of medical virology.

Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif

M. Imamura, N. Hiraga, K. Chayama, 2006, Antimicrobial Agents and Chemotherapy.

Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of Gastroenterology.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Hepatitis B Virus-Related Hepatocellular Carcinogenesis and Its Prevention

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Consistently Low Hepatitis B Virus DNA Saves Patients from Hepatocellular Carcinogenesis in HBV-Related Cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Journal of Gastroenterology.

A case of drug-induced acute liver failure caused by corticosteroids

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2022, Clinical Journal of Gastroenterology.

Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of hepatology.

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of hepatology.

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Journal of medical virology.

Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha‐fetoprotein in patients without hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Effect of Acute Self-Limited Hepatitis C Virus (HCV) Superinfection on Hepatitis B Virus (HBV)-Related Cirrhosis. Virological Features of HBV–HCV Dual Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Digestive Diseases and Sciences.

Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of hepatology.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Hepatology.

Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of gastroenterology and hepatology.

Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B

Yoshiyuki Suzuki, Mio Tanaka, M. Kobayashi, 2014, Journal of Gastroenterology.

Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of Clinical Virology.

Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Oncology.

Virological Response and Hepatocarcinogenesis in Lamivudine-Resistant Hepatitis B Virus Genotype C Patients Treated with Lamivudine plus Adefovir Dipivoxil

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Long-Term Follow-Up of HBeAg-Positive Young Adult Japanese Patients Treated with Corticosteroid Withdrawal Therapy for Chronic Hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2021, Oncology.

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

H. Nomura, K. Chayama, N. Izumi, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus‐related liver cancer

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan

H. Nomura, K. Chayama, N. Izumi, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Influence of HMG-CoA reductase inhibitor to virological response of peginterferon/ribavirin combination therapy in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008 .

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection

H. Yoshiji, K. Chayama, Y. Karino, 2017, Journal of Gastroenterology.

Vaniprevir plus peginterferon alfa‐2b and ribavirin in treatment‐experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies

K. Chayama, Y. Karino, A. Howe, 2016, Journal of gastroenterology and hepatology.

Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b

K. Chayama, Y. Karino, N. Izumi, 2013, Journal of viral hepatitis.

18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2019, Liver Cancer.

Clinical features of hepatitis B virus genotype A in Japanese patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2022, Clinical Journal of Gastroenterology.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of hepatology.

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Virology Journal.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of Gastroenterology.

Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan

F. Suzuki, Akira Komoto, K. Nakamura, 2018, Hepatology International.

Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of Gastroenterology.

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Drug design, development and therapy.

Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology communications.

Impact of hepatitis B core‐related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Alimentary pharmacology & therapeutics.

Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of Gastroenterology.

Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

Low hepatitis B virus core-related antigen is a predictor of absence in post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009 .

Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy

M. Imamura, K. Chayama, T. Okanoue, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Measurement of hepatitis B virus core‐related antigen is valuable for identifying patients who are at low risk of lamivudine resistance

M. Imamura, K. Chayama, T. Okanoue, 2006, Liver international : official journal of the International Association for the Study of the Liver.

Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

Pretreatment heterogeneous enhancement pattern of hepatocellular carcinoma can be new predictor for early response to lenvatinib

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2019 .

Viral Dynamics and Pharmacokinetics in Combined Interferon Alfa-2b and Ribavirin Therapy for Patients Infected with Hepatitis C Virus of Genotype 1b and High Pretreatment Viral Load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Hepatology.

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of hepatology.

Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Favorable efficacy of long‐term lamivudine therapy in patients with chronic hepatitis B: An 8‐year follow‐up study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of gastroenterology and hepatology.

Benefit of Lamivudine Therapy and Factors Associated with Clinical Outcome in Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B Virus Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of medical virology.

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long‐term lamivudine therapy for hepatitis B e antigen‐positive chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of medical virology.

Virological and biochemical relapse according to YMDD motif mutant type during long‐term lamivudine monotherapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, American Journal of Gastroenterology.

Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma

Yoshiyuki Suzuki, K. Ikeda, M. Kobayashi, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Liver Cancer.

Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Highly sensitive AFP‐L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre‐ and postoperatively

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.

Kenji Ikeda, Hiroki Ishikawa, Kazuaki Chayama, 2013, Journal of hepatology.

Adefovir Dipivoxil for Treatment of Breakthrough Hepatitis Caused by Lamivudine-Resistant Mutants of Hepatitis B Virus

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Clinical and virological features of non‐breakthrough and severe exacerbation due to lamivudine‐resistant hepatitis B virus mutants

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

HLA‐DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Liver international : official journal of the International Association for the Study of the Liver.

HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, The American journal of medicine.

Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Changes in viral loads of lamivudine‐resistant mutants during entecavir therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Changes in viral loads of lamivudine‐resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy

Hirotoshi Nakamura, H. Kumada, F. Suzuki, 2006, Journal of medical virology.

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Virology Journal.

Development of HCC in patients receiving adefovir dipivoxil for lamivudine‐resistant hepatitis B virus mutants

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of entecavir treatment for lamivudine‐resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of gastroenterology and hepatology.

Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients

H. Kumada, F. Suzuki, H. Miyakoshi, 2009, Journal of medical virology.

Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of Gastroenterology.

Clinical and virological effects of long‐term (over 5 years) lamivudine therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Interferon and lamivudine monotherapy on chronic hepatitis B in Japan

H. Kumada, F. Suzuki, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

A Pilot Study of Thymosin α1 Therapy for Chronic Hepatitis B Patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Internal medicine.

Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Oncology.

Necessities of interferon therapy in elderly patients with chronic hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, The American journal of medicine.

Long‐term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of gastroenterology and hepatology.

Precore Wild-Type Hepatitis B Virus with G1896 in the Resolution of Persistent Hepatitis B Virus Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Efficacy of switching to entecavir monotherapy in Japanese lamivudine‐pretreated patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of gastroenterology and hepatology.

Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology.

I shall be released (from infinite HBV nucleos(t)ide analog therapy): Japanese experience.

T. Umemura, F. Suzuki, M. Enomoto, 2021, Journal of hepatology.

Diagnostic Problems Caused by HBsAg Mutants – A Consensus Report of an Expert Meeting

P. Coursaget, Yoshiyuki Suzuki, O. Yokosuka, 2004, Intervirology.

Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

Relationship between Five-Year Histological Outcome and Serial Changes in Serum Alanine Aminotransferase in Patients with Biochemical and Virological Relapse after Interferon Treatment for Chronic Hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Intervirology.

Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.

K. Tadokoro, Toshikazu Yamaguchi, M. Nagano, 2011, Journal of virological methods.

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Gastroenterology.

Wild‐type precore and core promoter sequences in patients with acute self‐limited or chronic hepatitis B

A. Tsubota, Y. Suzuki, M. Kobayashi, 2004, Scandinavian journal of gastroenterology.

Increase of rtA181T mutant strains during entecavir therapy for a patient with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010 .

Long‐term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide‐naïve chronic hepatitis B patients

Y. Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of viral hepatitis.

Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

Randomized, controlled trial of natural interferon-α therapy for e-antigen-positive chronic hepatitis B patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002 .

Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Long-Term Presence of HBV in the Sera of Chronic Hepatitis B Patients with HBsAg Seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, The American journal of medicine.

Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of Gastroenterology.

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

N. Enomoto, K. Chayama, T. Pilot‐Matias, 2017, Journal of Gastroenterology.

Guidelines for the Management of Hepatitis C Virus Infection

N. Hiramatsu, Y. Asahina, S. Mochida, 2013 .

Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.

M. Buti, A. Lok, Y. Chong, 2019, Gastroenterology.

Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of medical virology.

Long-Term Clinical Remission Induced by Corticosteroid Withdrawal Therapy (CSWT) in Patients with Chronic Hepatitis B Infection: A Prospective Randomized Controlled Trial—CSWT with and Without Follow-Up Interferon-α Therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Digestive Diseases and Sciences.

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

M. Kudo, N. Hayashi, N. Hiramatsu, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Intervirology.

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2004, Journal of Gastroenterology.

Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Treatment Guidelines of Hepatitis C

N. Hayashi, N. Hiramatsu, N. Izumi, 2012 .

Change of hepatitis B virus genotypes in acute and chronic infections in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Digestive diseases and sciences.

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection

H. Kumada, M. Kano, F. Suzuki, 2012, Journal of viral hepatitis.

Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Cancer.

An encapsulated bulky abdominal abscess due to amoeba

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Clinical Journal of Gastroenterology.

Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Liver Cancer.

Recurrence Rate and Prognosis of Patients with Hepatocellular Carcinoma That Developed after Elimination of Hepatitis C Virus RNA by Interferon Therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Oncology.

Effectiveness of combination therapy of splenectomy and long‐term interferon in patients with hepatitis C virus‐related cirrhosis and thrombocytopenia

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, BMC Gastroenterology.

Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Oncology.

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib

J. Shindoh, Yoshiyuki Suzuki, Y. Eguchi, 2020, Internal medicine.

Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype.

K. Chayama, A. Tsubota, Y. Suzuki, 2001, Journal of virological methods.

Natural history of compensated cirrhosis in the Child‐Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

Yusuke Nakamura, M. Imamura, K. Chayama, 2010, Gut.

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.

Kenji Ikeda, Hiroki Ishikawa, Fei Yu, 2013, Journal of hepatology.

Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Internal medicine.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Intervirology.

Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Sustained Negativity for HCV-RNA over 24 or More Months by Long-Term Interferon Therapy Correlates with Eradication of HCV in Patients with Hepatitis C Virus Genotype 1b and High Viral Load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Randomized controlled clinical trial of lymphoblastoid interferon-α for chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001 .

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

H. Yoshiji, K. Chayama, Y. Karino, 2017, Journal of Gastroenterology.

Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of hepatology.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology.

Association of amino acid sequence in the PKR‐eIF2 phosphorylation homology domain and response to interferon therapy

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Hepatology.

Influence of amino‐acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2012, Intervirology.

Risk factors of hepatitis C virus‐related liver cirrhosis in young adults: Positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 Allele

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of medical virology.

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Yoshiyuki Suzuki, H. Sone, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Significance of oral glucose tolerance tests in non-alcoholic fatty liver disease patients with a fasting plasma glucose level of <126 mg/dL and HbA1c level of ≤ 6.4% in Japan.

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2015, Internal medicine.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Circulating microRNA‐122 levels are important predictor of hepatitis B virus surface antigen seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Liver Cancer.

High serum des‐gamma‐carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Cancer.

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real‐life settings

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Hepatology.

Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus–related cirrhosis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Cancer.

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Oncology.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Digestive Diseases and Sciences.

Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Journal of medical virology.

A Randomized Trial of Daclatasvir with Peginterferon Alfa-2B and Ribavirin for HCV Genotype 1 Infection

N. Hayashi, K. Chayama, J. Toyota, 2014, Antiviral therapy.

Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients

S. Ishida, S. Ozawa, Y. Ohno, 2008, Drug Metabolism and Disposition.

Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients

K. Chayama, Y. Karino, Yoshiyuki Suzuki, 2015, Journal of gastroenterology and hepatology.

Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2020, Internal medicine.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Internal medicine.

The Efficacy of Daclatasvir Plus Asunaprevir Combination Therapy with Chronic Hepatitis

K. Chayama, F. Suzuki, Fukiko Mitsui, 2017 .

hepatocarcinogenesis following eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015 .

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay.

K. Tadokoro, Toshikazu Yamaguchi, M. Nagano, 2013, Journal of virological methods.

Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Anticarcinogenic Impact of Interferon on Patients with Chronic Hepatitis C: A Large-Scale Long-Term Study in a Single Center

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2020, Clinical Journal of Gastroenterology.

Common genetic polymorphism of ITPA gene affects ribavirin‐induced anemia and effect of peg‐interferon plus ribavirin therapy

Yusuke Nakamura, M. Imamura, K. Chayama, 2011, Journal of medical virology.

Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Journal of medical virology.

Difference in malignancies of chronic liver disease due to non‐alcoholic fatty liver disease or hepatitis C in Japanese elderly patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Evaluation of long‐term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Association of HLA-DR14 with the Treatment Response in Japanese Patients with Autoimmune Hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Digestive Diseases and Sciences.

An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases

F. Kondo, Yoshiyuki Suzuki, K. Kinowaki, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Influence of the Hepatitis B e Antigen/ Anti-HBe Status on the Response to Lamivudine

F. Suzuki, 2003, Intervirology.

Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.

M. Imamura, K. Chayama, Y. Karino, 2022, Journal of hepatology.

Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Gut and liver.

Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Japanese journal of clinical oncology.

Previous Chemoembolization Response after Transcatheter Arterial Chemoembolization (TACE) Can Predict the Anti-Tumor Effect of Subsequent TACE with Miriplatin in Patients with Recurrent Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Oncology.

Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Usefulness and limitations of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of a no‐touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma

Kenji Ikeda, Tetsuya Hosaka, Miharu Hirakawa, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2014 in Japan].

F. Suzuki, 2015, Nihon rinsho. Japanese journal of clinical medicine.

Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma – direct ablative effects and a long‐term outcome

K. Ikeda, M. Kobayashi, H. Kumada, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Round-table discussion: Current treatment of hepatitis C based on experimental and clinical evidence

N. Enomoto, N. Hiramatsu, H. Kumada, 2007 .

Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, The American Journal of Gastroenterology.

The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis

J. Shindoh, Yoshiyuki Suzuki, I. Yasuda, 2022, Oncology.

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2022, Oncology.

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology International.

Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

M. Kudo, Y. Karino, T. Ide, 2021, BMC Gastroenterology.

with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1 b Infection and Limited Treatment Options

K. Chayama, Y. Karino, Yoshiyuki Suzuki, 2012 .

Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinicopathological assessment of steatohepatitic hepatocellular carcinoma.

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2021, Clinics and research in hepatology and gastroenterology.

Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients

A. Lok, Hwai I. Yang, T. Tseng, 2020, Clinical and translational gastroenterology.

Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease

K. Ikeda, H. Kumada, Y. Arase, 2009, Journal of Gastroenterology.

Efficacy and anticarcinogenic activity of interferon for hepatitis C virus‐related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Kanzo.

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

N. Enomoto, K. Chayama, T. Pilot‐Matias, 2017, Journal of Gastroenterology.

A novel entecavir-resistant virus with patient of lamivudine-resistant hepatitis B virus mutant

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2005 .

CASE REPORT: Clinical and virological analyses of a patient positive for hepatitis C virus‐RNA by branched DNA assay but negative for anti‐hepatitis C virus antibodies

K. Chayama, H. Kumada, F. Suzuki, 1997, Journal of gastroenterology and hepatology.

Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter.

Yoshiyuki Suzuki, M. Hashimoto, G. Watanabe, 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

Stepwise Hook Extension Technique for Radiofrequency Ablation Therapy of Hepatocellular Carcinoma

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Oncology.

Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, BMC Gastroenterology.

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology Research.

Randomized Controlled Trial Comparing the Efficacy of Impedance Control and Temperature Control of Radiofrequency Interstitial Thermal Ablation for Treating Small Hepatocellular Carcinoma

Kenji Ikeda, Tetsuya Hosaka, Masahiro Kobayashi, 2015, Oncology.

Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011 .

Successful control of ruptured hepatocellular carcinoma with radiofrequency ablation

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection

F. Kondo, Yoshiyuki Suzuki, K. Kinowaki, 2017, Internal medicine.

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Internal medicine.

Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2023, Cancers.

The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Internal medicine.

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Hepatology International.

Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology International.

Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma

Yoshiyuki Suzuki, K. Ikeda, M. Kobayashi, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

M. Kudo, N. Hayashi, N. Hiramatsu, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2023, Hepatology research : the official journal of the Japan Society of Hepatology.

Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2023, Oncology.

Transcatheter Arterial Chemotherapy with Miriplatin for Hepatocellular Carcinoma Patients with Chronic Renal Failure: Report of Three Cases

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Gut and liver.

CASE REPORT: Interferon-α for Reinfection with Hepatitis C Virus in Two Patients with Chronic Hepatitis C Who Had Responded to Previous Therapies

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Digestive Diseases and Sciences.

Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients

K. Chayama, Y. Karino, Yoshiyuki Suzuki, 2015, Journal of gastroenterology and hepatology.

TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Oncology.

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology Research.

Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Intervirology.

Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan

K. Chayama, A. Tamori, N. Izumi, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.

K. Tadokoro, Toshikazu Yamaguchi, M. Nagano, 2011, Journal of Virological Methods.

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of hepatology.